Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

ACT Biotech describes unique mechanism of action of ACTB-1003

Dec. 9, 2010

BI-6727 shows promise in phase I/II trial in acute myeloid leukemia

Dec. 9, 2010

Phase I/II data presented on MLN-8237 in hematological malignancies

Dec. 9, 2010

Phase II results for plitidepsin in peripheral T-cell lymphoma presented

Dec. 7, 2010

Activity seen with ARRY-520 in patients with relapsed/refractory multiple myeloma

Dec. 7, 2010

ACT Biotech describes activity of Aurora kinase inhibitor ACTB-1010

Dec. 7, 2010

Oncolytic prodrug BMS-817378 selected for clinical development

Dec. 7, 2010

Interim data from phase I trial of PF-03732010 in advanced solid tumors reveal good tolerability

Dec. 7, 2010

Preliminary efficacy reported in first-in-human trial of LFB-R603 in chronic lymphocytic leukemia

Dec. 7, 2010

TAvi6, a bispecific antibody targeting VEGF-A/ANG-2 inhibits angiogenesis in vivo

Dec. 3, 2010

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 26, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
Brain-computer interfaces are here but long road ahead
BioWorld
The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...
Case report links APOLD1 variant to vascular-type bleeding disorder
BioWorld Science
Vascular-type bleeding disorder (BDVAS) is a rare, autosomal dominant disorder mainly caused by impaired vascular integrity.
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...